These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 17671224)

  • 21. A rat model of metastatic spinal cord compression using human prostate adenocarcinoma: histopathological and functional analysis.
    Sarabia-Estrada R; Zadnik PL; Molina CA; Jimenez-Estrada I; Groves ML; Gokaslan ZL; Bydon A; Witham TF; Wolinsky JP; Sciubba DM
    Spine J; 2013 Nov; 13(11):1597-606. PubMed ID: 23810458
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Growth, regeneration, and tumorigenesis of the prostate activates the PSCA promoter.
    Watabe T; Lin M; Ide H; Donjacour AA; Cunha GR; Witte ON; Reiter RE
    Proc Natl Acad Sci U S A; 2002 Jan; 99(1):401-6. PubMed ID: 11752398
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development, progression, and androgen-dependence of prostate tumors in probasin-large T antigen transgenic mice: a model for prostate cancer.
    Kasper S; Sheppard PC; Yan Y; Pettigrew N; Borowsky AD; Prins GS; Dodd JG; Duckworth ML; Matusik RJ
    Lab Invest; 1998 Jun; 78(6):i-xv. PubMed ID: 9645768
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Real-time bioluminescence and tomographic imaging of gastric cancer in a novel orthotopic mouse model.
    Hu H; Liu J; Yao L; Yin J; Su N; Liu X; Cao F; Liang J; Nie Y; Wu K
    Oncol Rep; 2012 Jun; 27(6):1937-43. PubMed ID: 22407359
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Androgen-independent prostate cancer progression in the TRAMP model.
    Gingrich JR; Barrios RJ; Kattan MW; Nahm HS; Finegold MJ; Greenberg NM
    Cancer Res; 1997 Nov; 57(21):4687-91. PubMed ID: 9354422
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Noninvasive visualization of retinoblastoma growth and metastasis via bioluminescence imaging.
    Ji X; Cheng L; Wei F; Li H; Wang M; Tian Y; Chen X; Wang Y; Wolf F; Li C; Huang Q
    Invest Ophthalmol Vis Sci; 2009 Dec; 50(12):5544-51. PubMed ID: 19608529
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fluorescence-guided surgery of prostate cancer bone metastasis.
    Miwa S; Matsumoto Y; Hiroshima Y; Yano S; Uehara F; Yamamoto M; Zhang Y; Kimura H; Hayashi K; Yamamoto N; Bouvet M; Sugimoto N; Tsuchiya H; Hoffman RM
    J Surg Res; 2014 Nov; 192(1):124-33. PubMed ID: 24972740
    [TBL] [Abstract][Full Text] [Related]  

  • 28. EZC-prostate models offer high sensitivity and specificity for noninvasive imaging of prostate cancer progression and androgen receptor action.
    Seethammagari MR; Xie X; Greenberg NM; Spencer DM
    Cancer Res; 2006 Jun; 66(12):6199-209. PubMed ID: 16778194
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Transgenic mouse model expressing P53(R172H), luciferase, EGFP, and KRAS(G12D) in a single open reading frame for live imaging of tumor.
    Ju HL; Calvisi DF; Moon H; Baek S; Ribback S; Dombrowski F; Cho KJ; Chung SI; Han KH; Ro SW
    Sci Rep; 2015 Jan; 5():8053. PubMed ID: 25623590
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of prostate inflammation on lesion development in the POET3(+)Pten(+/-) mouse model of prostate carcinogenesis.
    Burcham GN; Cresswell GM; Snyder PW; Chen L; Liu X; Crist SA; Henry MD; Ratliff TL
    Am J Pathol; 2014 Dec; 184(12):3176-91. PubMed ID: 25455686
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Emergence of androgen independence at early stages of prostate cancer progression in Nkx3.1; Pten mice.
    Gao H; Ouyang X; Banach-Petrosky WA; Shen MM; Abate-Shen C
    Cancer Res; 2006 Aug; 66(16):7929-33. PubMed ID: 16912166
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vivo monitoring of tumor relapse and metastasis using bioluminescent PC-3M-luc-C6 cells in murine models of human prostate cancer.
    Jenkins DE; Yu SF; Hornig YS; Purchio T; Contag PR
    Clin Exp Metastasis; 2003; 20(8):745-56. PubMed ID: 14713108
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Micro-CT combined with bioluminescence imaging: a dynamic approach to detect early tumor-bone interaction in a tumor osteolysis murine model.
    Fritz V; Louis-Plence P; Apparailly F; Noël D; Voide R; Pillon A; Nicolas JC; Müller R; Jorgensen C
    Bone; 2007 Apr; 40(4):1032-40. PubMed ID: 17251073
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inactivation of Apc in the mouse prostate causes prostate carcinoma.
    Bruxvoort KJ; Charbonneau HM; Giambernardi TA; Goolsby JC; Qian CN; Zylstra CR; Robinson DR; Roy-Burman P; Shaw AK; Buckner-Berghuis BD; Sigler RE; Resau JH; Sullivan R; Bushman W; Williams BO
    Cancer Res; 2007 Mar; 67(6):2490-6. PubMed ID: 17363566
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Unopposed c-MYC expression in benign prostatic epithelium causes a cancer phenotype.
    Williams K; Fernandez S; Stien X; Ishii K; Love HD; Lau YF; Roberts RL; Hayward SW
    Prostate; 2005 Jun; 63(4):369-84. PubMed ID: 15937962
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expression and role of Foxa proteins in prostate cancer.
    Mirosevich J; Gao N; Gupta A; Shappell SB; Jove R; Matusik RJ
    Prostate; 2006 Jul; 66(10):1013-28. PubMed ID: 16001449
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Loss of MyD88 leads to more aggressive TRAMP prostate cancer and influences tumor infiltrating lymphocytes.
    Peek EM; Song W; Zhang H; Huang J; Chin AI
    Prostate; 2015 Apr; 75(5):463-73. PubMed ID: 25597486
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Conditional PTEN-deficient mice as a prostate cancer chemoprevention model.
    Koike H; Nozawa M; De Velasco MA; Kura Y; Ando N; Fukushima E; Yamamoto Y; Hatanaka Y; Yoshikawa K; Nishio K; Uemura H
    Asian Pac J Cancer Prev; 2015; 16(5):1827-31. PubMed ID: 25773832
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Castration triggers growth of previously static androgen-independent lesions in the transgenic adenocarcinoma of the mouse prostate (TRAMP) model.
    Johnson MA; Iversen P; Schwier P; Corn AL; Sandusky G; Graff J; Neubauer BL
    Prostate; 2005 Mar; 62(4):322-38. PubMed ID: 15389779
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Heterogeneous tumor evolution initiated by loss of pRb function in a preclinical prostate cancer model.
    Hill R; Song Y; Cardiff RD; Van Dyke T
    Cancer Res; 2005 Nov; 65(22):10243-54. PubMed ID: 16288012
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.